Apr 25, 2022

Medtronic Announces Scientific Data Presentations at The 2022 International Conference on Advanced Technologies and Treatments for Diabetes

Medtronic plc, the global leader in medical technology, today announced its participation at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking...

Medtronic plc, the global leader in medical technology, today announced its participation at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking place April 27-30, 2022. Medtronic will showcase clinically meaningful outcomes and extended study results for the MiniMed™ 780G System with Guardian™ 4 sensor, the most advanced Medtronic Advanced Hybrid Closed-Loop insulin delivery system which is currently available in 42 EMEA countries1, in addition to other research findings from the company’s comprehensive portfolio.

Scientific Presentations

The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research. Poster presentations will be available to all attendees for viewing throughout the conference.

Advanced Hybrid Closed-Loop Data Presentations

  • “Safety and glycemic control during the Medtronic advanced hybrid closed-loop pivotal trial in youth aged 7-17 years with type 1 diabetes (T1D)” – virtual oral presentation by Dorothy I. Shulman, M.D., Professor, University of South Florida, United States, on Friday, April 29 at 2:40 a.m. CT (9:40 CEST).
  • “Advanced hybrid closed-loop study in an adult population with type 1 diabetes (ADAPT): A randomized controlled study” – poster presentation by Pratik Choudhary, Professor, Leicester Diabetes Centre, University of Leicester, United Kingdom.
  • “Glycemic outcomes in pediatric and adult individuals with type 1 diabetes during MiniMed™ 780G system use with the Guardian™ 4 sensor” poster by John Shin, Ph.D., MBA, Senior Clinical Research Director, Medtronic Diabetes.

Automated Insulin Pump System Data Presentations

  • “Improved glycemic control with hybrid closed-loop (HCL) versus subcutaneous insulin infusion (CSII) therapy: Results from a randomized controlled trial” – oral presentation by Robert A. Vigersky, M.D., Chief Medical Officer, Medtronic Diabetes on Saturday, April 30 at 4:00 a.m. CT (11:00 CEST).
  • “Safety and glycemic control in Chinese adolescents and adults with type 1 diabetes (T1D) during a MiniMed™ 770G system clinical trial” – poster by Robert A. Vigersky, M.D.

InPen Data Presentations

  • “Use of decision tree modeling to identify factors associated with optimal time-in-range (TIR) during InPen™ smart insulin pen and continuous glucose monitoring (CGM) use” – poster presentation by Madison B. Smith, Ph.D., R.N., CDCES, R&D Clinical Product Manager, Medtronic Diabetes.

Other Data Presentations

  • “Assessing the use of the composite metric of mean glucose and glucose variability as an alternative to HbA1c for determining overall glycemic control” – poster by John Shin, Ph.D., MBA.

Medtronic Sponsored Events

The following symposium will feature detailed clinical trial data and discussions with Medtronic and independent speakers. Details are as follows:

  • “The MiniMed™ 780G system: Expanding to the wider population with type 1 diabetes" chaired by Chantal Mathieu, M.D., Ph.D., Professor of Internal Medicine, Katholieke Universiteit Leuven, Belgium on Thursday, April 28, 3:30-5:00 a.m. CT (10:30-12:00 CEST).  Panelist and data to be presented will include:

Chantal Mathieu, M.D., Ph.D.

The current state of type 1 diabetes

Pratik Choudhary

The ADAPT clinical study: From failing on MDI therapy to successful outcomes with the MiniMed™ 780G system

Tomasz Klupa, Professor, Head of the Center for Advanced Technologies in Diabetes

Department and Chair of Metabolic Diseases

Jagiellonian University Medical College, Poland

Successful MiniMed™ 780G System initiation in people with Type 1 diabetes naive to technology


Klemen Dovc, M.D., Ph.D., Assistant Professor, Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, University Children’s Hospital, and Faculty of Medicine, University of Ljubljana, Slovenia

First evidence with the MiniMed™ 780G system and FiAsp in adolescents: The FACT study

Ohad Cohen, M.D., Senior Global Medical Affairs Director, Medtronic Diabetes

Putting it all together: The MiniMed™ 780G system allowing patients to achieve 80% time in range

  • “Medtronic Smart MDI system: A novel combination of smart insulin pen and CGM to improve type 1 diabetes management” chaired by Robert Vigersky, M.D. on Thursday, April 28, 6:00 – 7:30 a.m. CT (13:00-14:30 CEST). Panelist and speakers to include:

Robert Vigersky, M.D.

The need for Smart MDI system

Rainer Strassburger-Lausen, Medical Affairs, Senior Program Manager, Medtronic Diabetes

Smart MDI system simulation

Rocio Harbison, M.D., Endocrinologist and Founder, Advanced Endocrinology and Diabetes Clinic, United States


Case presentation and experience

Robert Vigersky, M.D.

Clinical results: Poster/study presentation

  • “Successful initiation of the MiniMed™ 780G system in the wider population with type 1 diabetes” chaired by Ohad Cohen, M.D., on Friday, April 29, 2:00 – 3:00 a.m. CT (9:00-10:00 CEST). Panelist and speakers to include:

Ohad Cohen, M.D.

Welcome and introduction

Pilar Beato Vibora, M.D., Department of Paediatrics, Diabetes Technology Unit, Badajoz University Hospital

Evidence and best practices in adults

Henk Jan Aanstoot, M.D., Ph.D., Senior Medical Director, Diabeter, Netherlands


Evidence and best practices in pediatrics

About the Diabetes Business at Medtronic (www.medtronicdiabetes.com) 

Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health. 

1 MiniMed 780G System and Guardian™ 4 sensors are CE marked only and not commercially available or approved in the U.S.


For more information, contact:


Kendra Cassillo                                                                        Ryan Weispfenning
Public Relations                                                                        Investor Relations
+1-818-576-5611                                                                        +1-763-505-4626